Welcome to LookChem.com Sign In|Join Free
  • or
2-Butenedioic acid, 2-(4-Methoxyphenyl)-, 1,4-diMethyl ester, (2E)- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

488713-19-5

Post Buying Request

488713-19-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

488713-19-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 488713-19-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,8,8,7,1 and 3 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 488713-19:
(8*4)+(7*8)+(6*8)+(5*7)+(4*1)+(3*3)+(2*1)+(1*9)=195
195 % 10 = 5
So 488713-19-5 is a valid CAS Registry Number.

488713-19-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name dimethyl (E)-2-(4-methoxyphenyl)but-2-enedioate

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:488713-19-5 SDS

488713-19-5Downstream Products

488713-19-5Relevant academic research and scientific papers

Decarboxylative olefination of potassium benzoates via bimetallic catalysis strategy

Khalaj, Mehdi,Ghazanfarpour-Darjani, Majid,Taheri, Saeed,Sedaghat, Sajjad,Hoseyni, Seyed Jalal

, p. 2013 - 2019 (2018/09/25)

Abstract: A novel synthesis of styrene derivatives through decaroxylative olefination of potassium benzoates with alkynes using Pd2dba3/CuBr as catalyst system has been developed. The protocol proceeded smoothly and in most cases Z-alkene was the main product. Electron-rich potassium benzoates reacted more efficiently than those of electron-deficient substrates. Heteroaromatic and electron-deficient aryl alkynes were not consistent with this transformation. Graphical abstract: [Figure not available: see fulltext.].

Asymmetric hydrogenation of maleic acid diesters and anhydrides

Bernasconi, Maurizio,Mueller, Marc-Andre,Pfaltz, Andreas

supporting information, p. 5385 - 5388 (2014/06/09)

Asymmetric hydrogenation of maleic and fumaric acid derivatives with iridium catalysts based on N,P ligands provides an efficient route to chiral enantioenriched succinates. A new catalyst derived from a 2,6-difluorophenyl- substituted pyridine-phosphinite ligand was developed and enables the conversion of a wide range of 2-alkyl and 2-arylmaleic acid diesters into the corresponding succinates in high enantiomeric purity. Mixtures of cis/trans substrates can be hydrogenated in an enantioconvergent fashion with high enantioselectivity, and further enhances the scope of this transformation. The products are valuable chiral building blocks with a structural motif found in many bioactive compounds, such as metalloproteinase inhibitors. An attractive enantioselective route to 2-alkyl- and 2-aryl-substituted succinic acid derivatives is opened up by the asymmetric hydrogenation of maleic and fumaric acid derivatives, using the new catalyst [Ir(cod)L]BArF, derived from a 2,6-difluorophenyl-substituted pyridine-phosphinite ligand. The products are valuable chiral building blocks having a structural motif found in many bioactive compounds. cod=1,5-cyclooctadiene.

2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors

-

, (2008/06/13)

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 488713-19-5